PAUL MAMPILLYS’ AS AN INVESTOR AND EDITOR

Paul Mampilly is a former manager with the hedge fund and an American investor. He is also an editor of True Momentum, Profits Unlimited and Extreme Fortunes. In these newsletters he uses his vast skills, knowledge and experience that he acquired as an insider on Wall Street to advise his subscribers. He mainly guides them on the stocks to look out for and what is expected to happen to them. Visit Bloomberg to know more about Paul Mampilly.

Arriving in the United States from India as a young man, Paul Mampilly joined the Wall Street ranks. At the start of his career he joined Bankers Trust as a deputy portfolio manager. This was in 1991.Through the years he rose fast to more leadership roles in various banks. These include Private Swiss Bank, Bank of Scotland, Deutsche Bank and Sears.

Paul Mampilly’s outstanding leadership skills were recognised when he joined Kinetics Asset Management as its Key Manager. This investment grew from $50 million to $88 million in one year. Meaning Paul was not only able to initiate growth of 76% but was able to do so during the economic crisis of 2008 to 2009.

Personally his investment record is impressive. He made various investment gains before finally retiring at the age of 42. Some of his gains were made in Cemex at 266%, Facebook at 327%,Exact Sciences Corporation at 279%.

In his retirement he now focuses on recommending stocks that would be profitable to average Americans.

Learn: https://www.linkedin.com/in/paulmampilly

As an editor Paul Mampilly recently pitched a tease of a company that is leading the revolution in precision medicine. He gets the readers’ attention by writing of its breakthrough which is considered to be more significant than every medical Device, Drug and Vaccination Combined.

The Company’s name is Myriad Genetics (MYGN) and it is located in Utah in the Salt Lake City. Formed in early 1990’s, the Chief Executive Officer is a 25 year old biotech pioneer. Through his former contacts, he is approaching top scientific minds worldwide to come and work in this facility.

MYGN leads in evaluating whether an individual will develop a disease and verify which drug therapy they will respond to efficiently. They target different forms of cancer from Prostate, lung, breast and uterine. They also check for rheumatoid arthritis. All these investigations is done based on the persons’ genes.

This company is also involved in screening for hereditary cancer. These tests are their main source of revenue. Though the patent they had for them was annulled by the courts, newer tests have proved to be more superior to their competitors.

Paul Mampillys’ articles continue to impart knowledge in various sectors. Watch videos on Paul’s Youtube channel.

Comments are closed.